These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 15063832

  • 1. Glibenclamide inhibits thromboxane-mediated vasoconstriction by thromboxane receptor blockade.
    Pfister SL, Pratt PE, Kurian J, Campbell WB.
    Vascul Pharmacol; 2004 Jan; 40(6):285-92. PubMed ID: 15063832
    [Abstract] [Full Text] [Related]

  • 2. Glibenclamide inhibits thromboxane A2-induced contraction in human internal mammary artery and saphenous vein.
    Stanke F, Cracowski JL, Chavanon O, Magne JL, Blin D, Bessard G, Devillier P.
    Eur J Pharmacol; 1998 Jan 02; 341(1):65-71. PubMed ID: 9489857
    [Abstract] [Full Text] [Related]

  • 3. Thromboxane A2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen.
    Grosser T, Zucker TP, Weber AA, Schulte K, Sachinidis A, Vetter H, Schrör K.
    Eur J Pharmacol; 1997 Jan 29; 319(2-3):327-32. PubMed ID: 9042608
    [Abstract] [Full Text] [Related]

  • 4. Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle.
    Williams SP, Dorn GW, Rapoport RM.
    Am J Physiol; 1994 Aug 29; 267(2 Pt 2):H796-803. PubMed ID: 8067435
    [Abstract] [Full Text] [Related]

  • 5. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition.
    Pace-Asciak CR, Reynaud D, Demin P, Aslam R, Sun A.
    J Pharmacol Exp Ther; 2002 May 29; 301(2):618-24. PubMed ID: 11961065
    [Abstract] [Full Text] [Related]

  • 6. Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle.
    Dorn GW, Becker MW, Davis MG.
    J Biol Chem; 1992 Dec 05; 267(34):24897-905. PubMed ID: 1447225
    [Abstract] [Full Text] [Related]

  • 7. Interspecies differences in thromboxane A2 receptors are distinguished by glibenclamide.
    Kemp BK, McPherson GA.
    Eur J Pharmacol; 1998 Aug 07; 354(2-3):173-8. PubMed ID: 9754918
    [Abstract] [Full Text] [Related]

  • 8. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
    Morinelli TA, Oatis JE, Okwu AK, Mais DE, Mayeux PR, Masuda A, Knapp DR, Halushka PV.
    J Pharmacol Exp Ther; 1989 Nov 07; 251(2):557-62. PubMed ID: 2530338
    [Abstract] [Full Text] [Related]

  • 9. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M, Mais DE, Morinelli TA, Hamanaka N, Oatis JE, Halushka PV.
    J Pharmacol Exp Ther; 1992 Aug 07; 262(2):632-7. PubMed ID: 1386885
    [Abstract] [Full Text] [Related]

  • 10. Intracellular Ca2+ elevation and contraction due to prostaglandin F2alpha in rat aorta.
    Tosun M, Paul RJ, Rapoport RM.
    Eur J Pharmacol; 1997 Dec 11; 340(2-3):203-8. PubMed ID: 9537816
    [Abstract] [Full Text] [Related]

  • 11. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K, Halushka PV, Yan YT, Wong PY.
    J Pharmacol Exp Ther; 1994 Sep 11; 270(3):1192-6. PubMed ID: 7932171
    [Abstract] [Full Text] [Related]

  • 12. Glibenclamide is a competitive antagonist of the thromboxane A2 receptor in dog coronary artery in vitro.
    Cocks TM, King SJ, Angus JA.
    Br J Pharmacol; 1990 Jun 11; 100(2):375-8. PubMed ID: 2143093
    [Abstract] [Full Text] [Related]

  • 13. The pore-forming subunit of the K(ATP) channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro.
    O'Brien AJ, Thakur G, Buckley JF, Singer M, Clapp LH.
    Br J Pharmacol; 2005 Feb 11; 144(3):367-75. PubMed ID: 15655519
    [Abstract] [Full Text] [Related]

  • 14. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors.
    Okwu AK, Ullian ME, Halushka PV.
    J Pharmacol Exp Ther; 1992 Jul 11; 262(1):238-45. PubMed ID: 1378092
    [Abstract] [Full Text] [Related]

  • 15. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan 11; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 16. Potentiation of adrenaline vasoconstrictor response by sub-threshold concentrations of U-46619 in human umbilical vein: involvement of smooth muscle prostanoid TP(alpha) receptor isoform.
    Errasti AE, Luciani LI, Cesio CE, Tramontano J, Boveris D, Daray FM, Nowak W, Pelorosso FG, Rothlin RP.
    Eur J Pharmacol; 2007 May 21; 562(3):227-35. PubMed ID: 17362923
    [Abstract] [Full Text] [Related]

  • 17. Glibenclamide inhibits hypoxic relaxation of isolated porcine coronary arteries under conditions of impaired glycolysis.
    Mellemkjaer S, Nielsen-Kudsk JE.
    Eur J Pharmacol; 1994 Aug 03; 270(4):307-12. PubMed ID: 7805779
    [Abstract] [Full Text] [Related]

  • 18. Platelet and vascular thromboxane A2/prostaglandin H2 receptors. Evidence for different subclasses in the rat.
    Masuda A, Mais DE, Oatis JE, Halushka PV.
    Biochem Pharmacol; 1991 Jul 15; 42(3):537-44. PubMed ID: 1830482
    [Abstract] [Full Text] [Related]

  • 19. Characterization of the vascular thromboxane A2/prostaglandin endoperoxide receptor in rabbit aorta. Regulation by dexamethasone.
    Sessa WC, Halushka PV, Okwu A, Nasjletti A.
    Circ Res; 1990 Dec 15; 67(6):1562-9. PubMed ID: 2147131
    [Abstract] [Full Text] [Related]

  • 20. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals.
    Hecker M, Bara AT, Bauersachs J, Busse R.
    J Physiol; 1994 Dec 01; 481 ( Pt 2)(Pt 2):407-14. PubMed ID: 7738833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.